GeneDx Holdings Corp. (NASDAQ:WGS) Shares Sold by Oracle Investment Management Inc.

Oracle Investment Management Inc. reduced its position in shares of GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) by 2.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,023,468 shares of the company's stock after selling 22,300 shares during the period. GeneDx makes up about 42.8% of Oracle Investment Management Inc.'s portfolio, making the stock its biggest holding. Oracle Investment Management Inc. owned approximately 3.73% of GeneDx worth $78,664,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in WGS. MCF Advisors LLC grew its stake in GeneDx by 107.7% during the fourth quarter. MCF Advisors LLC now owns 351 shares of the company's stock worth $27,000 after purchasing an additional 182 shares during the period. Sterling Capital Management LLC grew its stake in GeneDx by 877.8% in the 4th quarter. Sterling Capital Management LLC now owns 352 shares of the company's stock valued at $27,000 after buying an additional 316 shares in the last quarter. Global Retirement Partners LLC bought a new stake in shares of GeneDx during the fourth quarter valued at about $28,000. Comerica Bank bought a new position in shares of GeneDx in the fourth quarter worth $50,000. Finally, Quarry LP purchased a new stake in GeneDx in the fourth quarter valued at approximately $78,000. Institutional investors own 61.72% of the company's stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. TD Securities reduced their price target on GeneDx from $135.00 to $110.00 and set a "buy" rating on the stock in a research note on Thursday, May 1st. Wells Fargo & Company decreased their target price on shares of GeneDx from $105.00 to $78.00 and set an "equal weight" rating for the company in a research note on Thursday, May 1st. TD Cowen boosted their target price on shares of GeneDx from $75.00 to $118.00 and gave the stock a "buy" rating in a report on Tuesday, January 7th. Finally, The Goldman Sachs Group raised their price target on GeneDx from $70.00 to $80.00 and gave the company a "neutral" rating in a report on Wednesday, February 19th. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $78.14.

Insider Transactions at GeneDx

In other news, CFO Kevin Feeley sold 402 shares of the business's stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $90.05, for a total value of $36,200.10. Following the completion of the sale, the chief financial officer now directly owns 5,044 shares in the company, valued at approximately $454,212.20. The trade was a 7.38 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Katherine Stueland sold 2,731 shares of the business's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $94.73, for a total transaction of $258,707.63. Following the transaction, the chief executive officer now owns 7,752 shares in the company, valued at approximately $734,346.96. The trade was a 26.05 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 139,390 shares of company stock valued at $13,043,288 in the last quarter. Insiders own 27.30% of the company's stock.

GeneDx Trading Down 6.0 %

NASDAQ:WGS traded down $3.94 on Tuesday, reaching $62.22. The stock had a trading volume of 971,046 shares, compared to its average volume of 722,147. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.40 and a quick ratio of 2.27. The company has a market cap of $1.75 billion, a price-to-earnings ratio of -31.71 and a beta of 1.96. The firm's fifty day moving average is $93.64 and its two-hundred day moving average is $82.95. GeneDx Holdings Corp. has a 12-month low of $18.80 and a 12-month high of $117.75.

GeneDx (NASDAQ:WGS - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The company reported $0.28 EPS for the quarter, topping the consensus estimate of $0.11 by $0.17. The business had revenue of $87.12 million for the quarter, compared to analysts' expectations of $79.90 million. GeneDx had a positive return on equity of 3.33% and a negative net margin of 17.12%. Equities analysts expect that GeneDx Holdings Corp. will post 0.97 EPS for the current fiscal year.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.